Medtronic Earns CE Mark For Affera Ablation System, Touts New PFA Results
Executive Summary
Results of the PULSED AF trial confirm that Medtronic’s PulseSelect pulsed field ablation is safe and effective for atrial fibrillation ablation. The company will likely incorporate PulseSelect into its Affera cardiac mapping and ablation system, which will soon be available in Europe.
You may also be interested in...
First PFA In The US: FDA Approves Medtronic’s PulseSelect For AF Ablation
Medtronic's PulseSelect is the first pulse field ablation technology to earn FDA approval and the company plans to launch it in early 2024. PulseSelect PFA earned a CE mark in November.
News We’re Watching: Boston Scientific Closes Relievant, Medtronic's PFA Earns CE Mark, And More
Medtech Insight's News We're Watching highlights medtech industry news developments you may have missed over the last few weeks.
Cardio Catch-Up: Boston Scientific's Farapulse PFA Shows Short Learning Curve In European Registry
Medtech Insight’s Cardiovascular Catch-Up highlights recent news on cardiovascular tech innovations that you may have missed. This edition recaps the presentation of results from EU PORIA, a European registry atrial fibrillation patients treated with Boston Scientific's Farapulse pulsed field ablation system.